Organigram Global (OGI) Non-Current Assets (2018 - 2025)
Organigram Global (OGI) posted quarterly Non-Current Assets of $201.5 million for Q3 2025, up 88.74% year-on-year from $106.8 million in Q3 2024, and up 88.74% on a QoQ basis from $106.8 million in Q3 2024.
Organigram Global (OGI) Non-Current Assets (2018 - 2025) Analysis & Trends
Organigram Global (OGI) has reported Non-Current Assets for 8 consecutive years, with $201.5 million the latest figure, recorded in Q3 2025.
- Quarterly Non-Current Assets rose 88.74% year-over-year to $201.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $690.6 million (down 4.76% YoY) and the FY2025 annual result came in at $201.5 million, up 88.74% from the prior year.
- Non-Current Assets climbed to $201.5 million in Q3 2025 per OGI's latest filing, from $106.8 million in the prior quarter.
- Over the last five years, Non-Current Assets for OGI reached as high as $276.0 million in Q3 2022 and fell as low as $106.3 million in Q3 2023.
- A 5-year average of $197.9 million and a median of $218.8 million in 2021 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets decreased 11.37% — and 2025, when it surged 88.74%.
- Year by year, Non-Current Assets stood at $236.0 million in 2021, then rose by 16.95% to $276.0 million in 2022, then slumped by 61.5% to $106.3 million in 2023, then advanced by 0.45% to $106.8 million in 2024, then jumped by 88.74% to $201.5 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $201.5 million, $106.8 million, and $106.3 million for Q3 2025, Q3 2024, and Q3 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 201.51 Mn |
| Sep 30, 2024 | 106.76 Mn |
| Sep 30, 2023 | 106.28 Mn |
| Aug 31, 2022 | 276.04 Mn |
| Aug 31, 2021 | 236.03 Mn |
| Feb 28, 2021 | 260.51 Mn |
| Nov 30, 2020 | 265.00 Mn |
| Aug 31, 2020 | 197.15 Mn |
| May 31, 2020 | 193.82 Mn |
| Feb 29, 2020 | 293.94 Mn |
| Aug 31, 2019 | 175.67 Mn |
| May 31, 2019 | 195.52 Mn |
| Aug 31, 2018 | 75.88 Mn |